NLS PHARMACEUTICS LTDON SHARES
Share · CH0523961370 · NLSP (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of NLS PHARMACEUTICS LTDON SHARES
No Price
Company Profile for NLS PHARMACEUTICS LTDON SHARES Share
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Company Data
Name NLS PHARMACEUTICS LTDON SHARES
Company NLS Pharmaceutics AG
Symbol NLSP
Website
https://nlspharma.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN CH0523961370
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Alexander Zwyer
Country Switzerland
Currency USD
Employees 0,0 T
Address The Circle 6, 8058 Zurich
IPO Date 2021-01-29
Stock Splits
| Date | Split |
|---|---|
| 31.10.2025 | 1:10 |
| 27.09.2024 | 1:40 |
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | NLSP |
More Shares
Investors who hold NLS PHARMACEUTICS LTDON SHARES also have the following shares in their portfolio:
